Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 2/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.34 |
| ▸ | SCD | O00767 | 3/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22534401 | 0.86 | STING1 (0.39) | KCNJ1STING1KDM2BTDO2EGLN1 | |
| SCHEMBL22534385 | 0.84 | MAPK1 (0.39) | KCNJ1STING1RETEGLN1 | |
| SCHEMBL30402315 | 0.77 | KCNJ1 (0.54) | KCNJ1TDO2KAT6AEGLN1 | |
| SCHEMBL18789269 | 0.77 | KCNJ1 (0.54) | KCNJ1TDO2KAT6AEGLN1 | |
| SCHEMBL17966640 | 0.76 | KCNJ1 (0.56) | KCNJ1EGLN1 | |
| SCHEMBL29520978 | 0.76 | KCNJ1 (0.56) | KCNJ1EGLN1 | |
| SCHEMBL24668344 | 0.75 | KCNJ1 (0.30) | KCNJ1 | |
| SCHEMBL24921536 | 0.73 | MAPT (0.36) | SCDTDO2RETEGLN1 | |
| SCHEMBL25650642 | 0.72 | KCNJ1 (0.59) | KCNJ1STING1 | |
| SCHEMBL24500141 | 0.71 | HPGD (0.42) | KCNJ1STING1SCDEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220233513-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2022-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233513-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | KCNJ1 3698/4885STING1 4048/4885SCD 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.